---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-23-000004"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:04:45.728588+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Instil Bio resumes Phase 1 trial of ITIL-306; initial data expected in 2023

## Summary
- Phase 1 trial of ITIL-306 (CoStAR-TIL) for NSCLC, ovarian, and renal cancer re-opened after voluntary pause.
- Initial safety, translational, and efficacy data from dose escalation cohorts expected in 2023.
- Resumption follows implementation of additional quality safeguards in manufacturing process.
- Company expects cash runway into 2025, excluding potential monetization of Tarzana manufacturing site.
- Recent reprioritization of clinical programs and corporate restructuring completed.

## SEC filing metadata
- accession: 0001789769-23-000004
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/0001789769-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976923000004/til-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-23-000004
- JSON: https://secwatch.observer/filing/0001789769-23-000004.json
- Plain text: https://secwatch.observer/filing/0001789769-23-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.